[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seroma-as-procedural-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seroma-as-procedural-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100640362","swedish-national-parotidectomy-study-snaps-drainless-versus-standard-surgery-100640362",false,"NCT07620184","Swedish National Parotidectomy Study (SNaPs): Drainless Versus Standard Surgery","A Prospective, Randomized, Multicenter Non-Inferiority Trial Evaluating the Safety of Parotidectomy Without Active Surgical Drainage (Svenska Nationella Parotisstudien)","SNaPs","Inclusion Criteria:\n\n* Patients scheduled to undergo partial or superficial parotidectomy without concurrent soft tissue surgery, in cases where a wound drain is traditionally used (extirpation of single adjacent lymph nodes is acceptable).\n* ASA physical status class 1-3.\n* Aged 18 years or older.\n* The patient understands the participant information and is able to make an informed choice.\n\nExclusion Criteria:\n\n* Previous parotid surgery on the same side\n* Tumour with parapharyngeal extension.\n* Ongoing or planned perioperative treatment with tranexamic acid.\n* Ongoing treatment with dual antiplatelet therapy (single agent therapy, such as Aspirin or Clopidogrel, is not an exclusion criterion).\n* Ongoing treatment with anticoagulants (NOAC, Warfarin) at the time of surgery. NOAC must be discontinued at least 24 hours before surgery.\n* Ongoing treatment with low molecular weight heparin in doses higher than: Fragmin 5000 IU\u002Fday, Clexane 40 mg\u002Fday, or Innohep 4500 IU\u002Fday.Ongoing treatment for malignancy.Known coagulation disorder.\n* Platelet count \\\u003C150 x 10⁹\n* PK-INR \\>1.2.\n* Hb \\\u003C120 g\u002FL.\n* APTT \\>42s.\n* Preoperative impaired facial nerve function on the affected side (Sunnybrook Facial Grading System score \\\u003C90).\n* Supplementary postoperative treatment such as radiotherapy or extended surgery.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study The purpose of this study is to find out if it is safe to perform surgery on the parotid gland (the large salivary gland in front of the ear) without using a wound drain. A wound drain is a small plastic tube used to remove excess fluid from the surgical site after the operation. Currently, using a drain is the standard practice in Sweden, which often means patients must stay in hospital overnight. Researchers want to see if skipping the drain is just as safe and if it could allow more patients to return home on the same day as their surgery.\n\nWhat happens during the study\n\nParticipants in this study will be randomly assigned to one of two groups during their surgery:\n\nGroup 1: Will receive the standard treatment with a wound drain.\n\nGroup 2: Will have the surgery performed without a wound drain.\n\nApart from the use of a drain, all participants will receive the same surgical care. After the operation, researchers will monitor the healing process. Participants will be asked to fill out questionnaires about their health and any symptoms at one week and six months after their surgery.\n\nThe goal of the study The main goal is to compare the safety of the two methods. Researchers will look at whether there is any difference in the number of complications, such as fluid build-up (seroma), bleeding, or infections, between those who had a drain and those who did not. The study also aims to evaluate if avoiding a drain improves the patient's quality of life and if it is a more cost-effective approach for the healthcare system.",[27,28,29],"Parotid Neoplasms","Post-operative Complications","Seroma as Procedural Complication",[31,32,33,34,35,36,37,38,39,40],"Parotidectomy","Surgical drainage","Wound drains","Postoperative complications","Seroma","Hematoma","Randomised controlled trial","Non-inferiority","Salivary gland surgery","Quality of life","RECRUITING","2026-06-02",{"date":44,"type":45},"2026-06-04","ACTUAL",{"date":47,"type":45},"2026-05-06",{"date":49,"type":21},"2032-12",{"name":51,"class":52},"Uppsala University Hospital","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100560277","seroma-and-hematoma-rates-maxigesic-iv-vs-ketorolac-in-breast-cancer-surgery-100560277","NCT06575049","Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients","Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg\u002FdL or less\n* Patients with adequate liver function Bilirubin, AST\u002FALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form","FEMALE","20 Years","70 Years",{"count":65,"type":21},60,"3 Months","OBSERVATIONAL","The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.",[70,71,29,72],"Breast Cancer","Post-Operative Hematoma","Post-Op Complication","NOT_YET_RECRUITING","2024-09-02",{"date":76,"type":45},"2024-09-19",{"date":78,"type":21},"2025-05-01",{"date":80,"type":21},"2026-02-20",{"name":82,"class":52},"Seoul National University Hospital"]